Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Stefanie SchüpkeFranz-Josef NeumannMaurizio MenichelliKatharina MayerIsabell BernlochnerJochen WöhrleGert RichardtChristoph LiebetrauBernhard WitzenbichlerDavid AntoniucciIbrahim AkinLorenz Bott-FlügelMarcus FischerUlf LandmesserHugo A KatusDirk SibbingMelchior SeyfarthMarion JanischDuino BoncompagniRaphaela HilzWolfgang RottbauerRainer OkrojekHelge MöllmannWillibald HochholzerAngela MiglioriniSalvatore CassesePasquale MolloErion XhepaSebastian KufnerAxel StrehleStefan LeggewieAbdelhakim AllaliGjin NdrepepaHelmut SchühlenDominick J AngiolilloChristian W HammAlexander HapfelmeierRalph TölgDietmar TrenkHeribert SchunkertKarl-Ludwig LaugwitzAdnan Kastratinull nullPublished in: The New England journal of medicine (2019)
Among patients who presented with acute coronary syndromes with or without ST-segment elevation, the incidence of death, myocardial infarction, or stroke was significantly lower among those who received prasugrel than among those who received ticagrelor, and the incidence of major bleeding was not significantly different between the two groups. (Funded by the German Center for Cardiovascular Research and Deutsches Herzzentrum München; ISAR-REACT 5 ClinicalTrials.gov number, NCT01944800.).